
Last week's license, collaboration and commercialization agreement between Spanish dermatology company Almirall and Danish pharmaceutical firm MC2 Therapeutics on European rights to the drug Wynzora closes a pipeline gap in Almirall's portfolio of treatments for patients with psoriasis.
At the moment, Almirall only has two novel products against psoriasis: Ilumetri and Skilarance, which target severe and moderate-to-severe psoriasis, respectively. The firm will aim Wynzora at mild-to-moderate psoriasis.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app